Precision BioSciences, Inc. (DTIL)
| Market Cap | 170.30M +159.9% |
| Revenue (ttm) | 45.06M +3,473.0% |
| Net Income | -52.73M |
| EPS | -2.59 |
| Shares Out | 27.60M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 246,136 |
| Open | 6.04 |
| Previous Close | 6.03 |
| Day's Range | 5.98 - 6.20 |
| 52-Week Range | 3.53 - 9.62 |
| Beta | 1.28 |
| Analysts | Strong Buy |
| Price Target | 29.40 (+376.5%) |
| Est. Earnings | Nov 2, 2026 |
About DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for DTIL stock is "Strong Buy." The 12-month stock price target is $29.4, which is an increase of 376.50% from the latest price.
News
Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: H.C. Wainwright 28th Annual Global Investment Conference
The ARCUS platform underpins two differentiated clinical programs: PBGENE-HBV for hepatitis B, showing durable cccDNA elimination and improved safety, and PBGENE-DMD for Duchenne muscular dystrophy, with initial dosing and safety data expected by year-end. Strong financial runway and regulatory designations support advancement toward key milestones.
BioSciences doses first patient in Phase 1/2 FUNCTION-DMD clinical trial
Precision BioSciences (DTIL) announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of Duchenne muscular dystrophy, or...
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to present data from OTC-HOPE trial of ECUR-506
iECURE announced that data from the ongoing OTC-HOPE clinical trial evaluating ECUR-506 for neonatal-onset ornithine transcarbamylase deficiency will be featured in an oral presentation at the Annual ...
Precision BioSciences Earnings release: Q2 2026
Precision BioSciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Precision BioSciences Quarterly report: Q2 2026
Precision BioSciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
Precision BioSciences reports Q2 EPS ($1.26) vs. ($2.13) last year
Reports revenue $0 vs. $18,000 last year. “The second quarter marked a defining moment for Precision BioSciences (DTIL) and the hepatitis B field, with the first clinical biopsy evidence that…
Precision BioSciences sees cash runway through 2028
As of June 30, 2026, Precision had approximately $112.4 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, continued fiscal and operat...
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces changes to its senior leadership team
Precision BioSciences (DTIL) announced changes to its senior leadership team. Alex Kelly, currently Chief Financial Officer, has been promoted to the newly created role of Chief Operating Officer wher...
Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces grant of inducement awards
Precision BioSciences (DTIL) announced that, on July 5, the Compensation Committee of Precision’s Board of Directors approved the grant of inducement awards to new employees under the Precision BioSci...
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences announces addition to the Russell 2000 Index
Precision BioSciences (DTIL) announced its addition to the Russell 2000 Index, effective at the close of U.S. equity markets on June 26, 2026, according to the final list of additions…
Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of Precision BioSciences (DTIL) with an Outperform rating and $20 price target The firm sees the company’s Duchenne muscular dystrophy program as perhaps the only gene t...
Precision BioSciences Transcript: Jefferies Global Healthcare Conference 2026
The company showcased clinical progress in HBV and DMD gene editing, with PBGENE-HBV demonstrating direct cccDNA elimination and durable biomarker responses, and the DMD program advancing toward initial clinical data. Cash runway extends through 2028, supporting ongoing trials and key milestones.
Precision BioSciences Transcript: Study update
PBGENE-HBV demonstrated the first clinical evidence of cccDNA elimination in chronic hepatitis B, with all patients showing undetectable pgRNA post-treatment and broad S-antigen declines. The therapy showed a favorable safety profile with manageable adverse events, supporting further development and plans to assess viral cure by stopping NUCs in select patients.
Precision BioSciences Press release: Study update
Precision BioSciences issued a press release on May 27, 2026, disclosing material business information to investors.
Precision BioSciences Slides: Study update
Precision BioSciences has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Precision BioSciences presents new data from ELIMINATE-B study at EASL
Precision BioSciences (DTIL) announced the presentation of new and late-breaking clinical data from the ELIMINATE-B study evaluating PBGENE-HBV at the European Association for the Study of the Liver, ...
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapi...
Precision BioSciences Transcript: AGM 2026
The meeting highlighted progress in gene editing programs, strong financial positioning, and approval of all six proposals, including director elections and governance amendments. No questions were raised by shareholders, and final voting results will be published in a Form 8-K.